TIGIT and ovarian carcinoma: Our demonstration that blockade of the paired NK inhibitory receptor TIGIT further augmented NK cytotoxicity against OV-infected cells suggests that the combination of oncolytic adenovirus and TIGIT blockade may be a viable treatment strategy in ovarian cancer.